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Flavonoids are a diverse group of plant secondary metabolites, known to reduce inflam-
matory bowel disease symptoms. How they achieve this is largely unknown. Our study 
focuses on the gut epithelium as it receives high topological doses of dietary constitu-
ents, maintains gut homeostasis, and orchestrates gut immunity. Dysregulation leads to 
chronic gut inflammation, via dendritic cell (DC)-driven immune responses. Tomatoes 
engineered for enriched sets of flavonoids (anthocyanins or flavonols) provided a unique 
and complex naturally consumed food matrix to study the effect of diet on chronic 
inflammation. Primary murine colonic epithelial cell-based inflammation assays consist 
of chemokine induction, apoptosis and proliferation, and effects on kinase pathways. 
Primary murine leukocytes and DCs were used to assay effects on transmigration. 
A murine intestinal cell line was used to assay wound healing. Engineered tomato extracts 
(enriched in anthocyanins or flavonols) showed strong and specific inhibitory effects on 
a set of key epithelial pro-inflammatory cytokines and chemokines. Chemotaxis assays 
showed a resulting reduction in the migration of primary leukocytes and DCs. Activation 
of epithelial cell SAPK/JNK and p38 MAPK signaling pathways were specifically inhib-
ited. The epithelial wound healing-associated STAT3 pathway was unaffected. Cellular 
migration, proliferation, and apoptosis assays confirmed that wound healing processes 
were not affected by flavonoids. We show flavonoids target epithelial pro-inflammatory 
kinase pathways, inhibiting chemotactic signals resulting in reduced leukocyte and DC 
chemotaxis. Thus, both anthocyanins and flavonols modulate epithelial cells to become 
hyporesponsive to bacterial stimulation. Our results identify a viable mechanism to 
explain the in vivo anti-inflammatory effects of flavonoids.
Keywords: diet, flavonoid, inflammatory bowel disease, epithelial, dendritic cell
inTrODUcTiOn
Chronic disease is a growing problem, in terms of direct costs to societies and governments, dis-
ability adjusted life years, and quality of life. In 2012, among civilian, non-institutionalized US 
adults, 49.8% (117 million) had at least 1 of 10 selected chronic conditions (1). Chronic disease is 
strongly associated with life-style factors, particularly diet (2–5). Fundamental research is required 
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to understand the mechanisms that link diet to health, so that 
our understanding can go beyond general recommendations, and 
make predictions, particularly in the form of advice targeted to 
specific groups of affected individuals.
Natural plant products are known to have anti-inflammatory 
properties (6), among which are the flavonoids. Flavonoids 
are specialized polyphenolic compounds abundant in many 
fruits and vegetables. They have been demonstrated to have 
several beneficial health effects in age-related diseases, such 
as cardiovascular disease and cancer (7) and with respect to 
chronic inflammation; asthma and inflammatory bowel disease 
(IBD) (8). This study seeks to address the anti-inflammatory 
mechanisms of action of plant products in a primary cell-based 
model, using an engineered tomato as a comparative whole food. 
We hypothesize that flavonoids act primarily on the epithelial 
layer of the gut to inhibit communication to underlying DCs. 
This would have the effect of reducing the level of acute gut 
inflammation becoming chronic.
Inflammatory bowel disease describes two idiopathic chro nic 
inflammatory conditions of the gut: Chron’s disease and ulcera-
tive colitis. The etiology of IBD remains unknown, although 
both conditions are usually considered multifactorial disorders 
arising from a breakdown in mucosal immune tolerance to resi-
dent intestinal microbes (9). IBD is characterized by alternating 
phases of clinical remission and relapse (10). It is a growing global 
health burden and is often associated with industrialization, with 
0.5–1% of the UK population being affected (11). A variety of 
pharmacological and surgical treatments exist with prescription 
based on disease severity (12). However, these treatments are 
often life-long and may have a limited efficacy and detrimental 
side effects (13). Dietary intervention as an IBD therapeutic is 
an attractive approach as it could be used to not only attenuate 
the immune system, potentially making it hyporesponsive, but 
also because high topological doses and absence of side effects 
of normal dietary components could potentially promote longer 
remission phases. Promotion and maintenance of patient remis-
sion remains a long-term goal in IBD therapeutics, which is 
where preventative actions, especially dietary changes could have 
a real impact.
The effects of flavonoids on chronic gut inflammation have 
been demonstrated in animal-based models (14) and recently in 
clinical trials (15). Positive effects include, reduction of bleeding, 
improvement in stool consistency, improved colon histological 
appearance, decreased weight loss, and protection from colon 
shortening in rodent studies (14). Flavonoids are likely to be 
pleiotropic (16). However, several potential molecular targets 
have been proposed, including key inflammatory signaling path-
ways (17). This has an advantage over drugs designed to single 
targets, potentially countering the immune system’s high degree 
of redundancy.
Many immune cells play a role in IBD, our study focused on 
the boundary epithelial cells and their interaction with mucosal 
dendritic cells (DCs) and in particular on the cytokines and 
chemokines that mediate interactions between the epithelium 
and DCs. DCs provide the link between the innate and adaptive 
immune systems. Intestinal inflammation is characterized by the 
influx and accumulation of activated immune cells, in particular 
DCs, into the gut mucosa (18) with increased numbers of DCs 
believed to be central in the pathogenesis of colitis (19).
In parallel to reducing chronic inflammation, healing of the 
gut mucosa is regarded as an important factor in the treatment 
of IBD (20). This healing is driven by the STAT3 kinase signaling 
pathway (21). Mucosal healing occurs in several stages, firstly 
by epithelial restitution where adjacent epithelial cells migrate 
to cover the wound area (22). Then epithelial cell proliferation 
increases the cellular pool at the wound site, followed by dif-
ferentiation (22). Any proposed therapeutic treatment for IBD 
needs to demonstrate no adverse effects on the processes of 
healing or cause aberrant apoptosis, to be effective in long-term 
disease management.
Plant biotechnology offers methods for targeted enhancement 
of the levels of different phytonutrients in widely consumed 
plant foods, such as tomatoes. Many health-benefit studies 
have been confounded because purified phytochemicals fail to 
have the same effects as they do in food. These problems are 
avoided by addressing the effects of each phytonutrient and 
combinations at equivalent levels in a matched food matrix. 
Our study takes a unique approach, by using an engineered food 
as a comparative tool to study the anti-inflammatory effects 
of diet.
MaTerials anD MeThODs
Preparation and analysis of aqueous 
Tomato extracts
Aqueous tomato extracts were prepared from Del/Ros1N 
(H-antho) and AtMYB12 (H-flav) lines (23). After homogeniza-
tion, supernatants were clarified by centrifugation, aliquoted 
(single use), and stored at −80°C. To quantify the major 
phenolics present in the tomato extracts, we used the follow-
ing phenolics as standards: chlorogenic acid, rutin, kaempferol 
rutinoside, quercetin, and cyanidin. Samples were analyzed on 
a Prominence/Nexera UHPLC equipped with an ion-trap ToF 
mass spectrometer (Shimadzu). Phenolics were separated on a 
100 ×  2.1 mm 2.6 μ Kinetex EVO C18 column (Phenomenex) 
using the following gradient of acetonitrile (solvent A) versus 
1% formic acid in water (solvent B) run at 500  µL  min−1 and 
40°C: 0 min, 2% A; 0.5 min, 2% A; 5 min, 10% A; 17 min, 30% 
A; 25 min, 90% A; 25.8 min, 90% A; 26 min, 2% A; 30.1 min, 
and 2% A. Detection was performed using UV/visible absorb-
ance by collecting spectra from 200 to 600 nm at 6.25 Hz, and 
by positive mode electrospray MS. Flavonoids were quantified 
from UV absorbance at 350 nm, chlorogenic acid at 325 nm, and 
both with bandwidth of 4  nm. Anthocyanins were quantified 
from visible absorbance at 500–550 nm, following subtraction of 
a reference of 590–600 nm. MS data were used to confirm the 
presence and identity of compounds quantified by UV/visible 
absorbance.
cell isolation and culture
Male C57BL/6 mice at 6–8 weeks of age were used throughout. 
Murine colonic epithelial cell (CEC) isolation and culture were 
performed as described in Baumgart et  al. (24). Briefly, colons 
3Tomlinson et al. Flavonoids Inhibit IBD by Kinase Signaling
Frontiers in Nutrition | www.frontiersin.org December 2017 | Volume 4 | Article 61
were isolated, cleaned, and the epithelial layer dissociated by 
selective protease digestion. CECs were cultured for 3  days at 
37°C with 5% CO2 and 95% air. CECs were plated at a density 
of 1.5 ×  106 CEC cells per well in a 6-well plate with 2  mL of 
media, with or without the addition of aqueous tomato extracts 
(each repeat is a pooled sample of five biological replicates). 
Cell preparations were assayed for epithelial cell enrichment by 
staining with cytokeratin (Sigma F3418) and analyzed by flow 
cytometry (Beckman Coulter FC500).
cytokine and chemokine analysis
Cells were incubated with aqueous tomato extracts, added to a 
2% final concentration (volume/volume ratio), 40 µL in 1,960 µL 
of media. After 4 h of incubation with tomato extracts, they were 
microbe-associated molecular pattern (MAMP) stimulated— 
1 µg/mL of peptidoglycan (Staphylococcus aureus, Sigma), 1 µg/mL 
of muramyl dipeptide (Bachem), and 1  µg/mL of lipopolysac-
charide (Salmonella typhosa, Sigma). After 3 days of culture, the 
conditioned media were clarified by centrifugation.
Murine trans-immortalized intestinal cell-line (m-ICcl2) 
cells were used as a model of a polarized gut barrier, grown to a 
confluent monolayer and incubated for 4 h prior to stimulation, 
with and without tomato extracts. Aqueous tomato extracts were 
added to a 2% final concentration (v/v). The conditioned media 
were collected 24 h post-stimulation.
Conditioned media from both cell types were then analyzed 
using cytometric bead arrays (CBA, BD Bioscience), according 
the manufacturer’s instructions. Three replicates of each experi-
ment were assayed. Mean fluorescence intensity values were 
converted to pg/mL by polynomial regression analysis, calcu-
lated from standard curves generated from recombinant protein 
standards. The mean values and SD were calculated from three 
replicates. Each replicate is a pooled sample of five mice. Key 
inflammatory chemokines were selected based on their expres-
sion in mouse and human CECs (25, 26) and their upregulation 
in experimental mouse colitis models and human IBD patients 
(23, 27–29).
chemotaxis assays
A transwell (Boyden chamber) assay was used to determine the 
effect of reduced chemokines on the movement of primary murine 
DCs, with recombinant chemokines at the same concentrations, 
to replicate control and flavonoid addition. The following recom-
binant chemokines were added to the lower chambers to mimic 
the results seen with CECs and 2% aqueous wild-type extract: 
CCL2—3,827 pg/mL (R&D Systems 479-JE); CXCL1—2,406 pg/
mL (R&D Systems 453-KC); CCL5—228 pg/mL (R&D Systems 
478-MR); CCL3—136 pg/mL (R&D Systems 450-MA-010); and 
CCL4—125 pg/mL (R&D Systems 451-MB). To mimic the results 
seen with CECs and the average value with 2% high-flavonol 
tomato extract addition (CCL2—789 pg/mL), chemokines were 
diluted in serum free Hanks’ Balanced Salt solution. Mouse 
spleen polymorphonuclear leukocytes (CD45+, BD Bioscience 
563890 and isotype control BD Bioscience 562603) were isolated 
according to Inaba et al. (30) with a optiprep-based flotation pro-
tocol (Axis-shield) and added to the top chamber of 5-µm pore 
size inserts (Costar) in 24-well plates. Fluorescence-activated cell 
sorting (FACS) gave a 30–40% enrichment of DCs. Using live 
staining with both CD11c+ (BD Bioscience 560583 and isotype 
control BD Bioscience 560555) and MHC-II+ antibodies (BD 
Bioscience 562366 and isotype control BD Bioscience 560784). 
For each assay the cells were pooled so that DC numbers were 
consistent.
Chemotaxis assays were incubated at 37°C for 2 h. Chemotaxis 
assays were replicated three times. Each replicate was a pooled 
sample of mouse spleen polymorphonuclear leukocytes from 10 
mice. Cell numbers in the lower chambers were counted by FACS 
as well as by hemocytometer. For hemocytometer counts, total 
numbers of cells were counted three times for each sample and 
mean values and SD around the mean were calculated. For FACS 
analysis, the entire content of the lower chamber was stained to 
detect DCs with the following antibodies: CD45, CD11c, and 
MHCII. Half the lower chamber volume was assayed by FACS 
and DC cell counts were extrapolated back to the original 
volume. Some of the MHCII+/CD11C+ labeled cells might have 
included a macrophage subset.
To allow a checkerboard analysis matrix to be generated, 
recombinant chemokines were added to either upper or lower 
chambers, or both at previously stated concentrations, to discern 
between chemokinesis and chemotaxis. Serum free HBSS was 
added to the chambers as a media-only control. The following 
gating strategy for FACS analysis was used; single-cell events were 
gated for using forward and side scatter parameters. Following 
this, unstained cells, isotype (to determine non-specific antibody 
binding) and fluorescence minus one controls (to determine gat-
ing boundaries in multicolor flow cytometry experiments) were 
run. A bivariate histogram was used to determine the gating for 
each cell type.
Phosphorylation state of inflammation 
cascade Kinases
An ELISA assay (Cell Signaling Technology 7276) containing 
members of key inflammatory signaling pathways, including 
NF-κB, SAPK/JNK, p38 MAPK, and STAT3, was used. Primary 
murine CECs were isolated as previously described (24) and 
normalized to 1.5 ×  106/mL by hemocytometer and cultured 
for 4 h in the presence or absence of tomato extracts. Aqueous 
tomato extracts were added to a 2% final concentration (volume/
volume ratio). The cultures were then stimulated with bacte-
rial peptides (MAMPs); 1  µg/mL of peptidoglycan (S. aureus, 
Sigma), 1 µg/mL of muramyl dipeptide (Bachem), and 1 µg/mL 
of lipopolysaccharide (S. typhosa, Sigma) for 30  min, except 
the uninduced control. The assay was replicated three times. 
Sti mulated cells were then lysed immediately following the pro-
tocol recommended by the manufacture. Protein concentrations 
were checked by Lowry protein assay (Bio Rad 500-0120), and 
samples were normalized to 700 µg/mL. Cell lysates were diluted 
1:1 with sample dilutant (Cell Signaling Technology) and 200 µL 
of diluted lysates were used per well.
To determine if the ELISA results were significantly different, 
single-factor ANOVA analysis was performed.
TaBle 1 | Quantification by LC/MS analysis of the most abundant polyphenols 
in aqueous extracts of high-anthocyanin (H-antho), high-flavonol (H-flav), and 
control wild-type (WT) tomato fruit.
compound Wild Type h-antho h-flav
CGA 72.35 (15.96±) 197.06 (3.16±) 472.63 (9.59±)
KaeRut 10.86 (0.16±) 47.27 (0.72±) 2853.56 (52.63±)
Rut 62.62 (4.39±) 99.86 (3.63±) 1021.31 (16.58±)
KaeRutGlc 0 4.25 (0.61±) 443.67 (8.08±)
KaeGlc 6.22 (0.46±) 12.54 (0.56±) 561.66 (16.62±)
QueRutGlc 5.43 (0.51±) 1.36 (2.36±) 63.09 (0.27±)
DelCouRutGlc  
PetCafRutGlc*
0 217.96 (1.32±) 0
PetCouRutGlc 0 238.46 (1.61±) 0
DelCafRutGlc 0 20.11 (0.40±) 0
All values expressed as micromolar. Mean values are shown with ± SD. CGA, 
chlorogenic acid; KaeRut, Kaempferol-rutinoside; Rut, Rutin; KaeRutGlc, Kaempferol-
rutinoside-glucoside; KaeGlc, Kaempferol-glucoside; QueRutGlc, Quercetin-rutinoside-
glucoside; DelCouRutGlc, Delphinidin-glucoside-coumaroyl-rutinoside; PetCafRutGlc, 
Petunidin-glucoside-caffeoyl-rutinoside; PetCouRutGlc, Petunidin-glucoside-
coumaroyl-rutinoside; DelCafRutGlc, Delphinidin-glucoside-caffeoyl-rutinoside.
*The DelCouRutGlc MS peak also contains traces of a minor anthocyanin, 
PetCafRutGlc
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Wound healing (gap closure assays)
The m-ICcl2 cell line was cultured in 12-well plates and serum 
starved for 24 h, pre-assay. Cells were incubated with aqueous 
tomato extracts at 2% final concentration (v/v) for 4  h then 
a single scratch was made to the confluent monolayer with a 
P1000 pipette tip. Wounded monolayers were washed three 
times with serum-free media. Assays were replicated three 
times. Microscopy images were taken on a Zeiss Axiovert 200 M 
at time 0 h, and scaled wound width measurements were taken 
with Zeiss Axiovision 4 software. A permanent mark on the 
underside of each well, intersecting a scratched area, acted as 
a reference point. Cells were incubated for a further 18 h with 
and without tomato extracts and measurements taken again at 
the reference point.
To investigate the effects of flavonoids on wound-associated 
proliferation, BrdU incorporation assays were performed. BrdU 
labeling reagent (Zymed 00-0103) was added at a 1:100 concen-
tration at T-0 and then removed with a media change (X3) 3 h 
later. These assays were also replicated three times. Cells were 
fixed at 18 h and immunohistochemistry (anti-BrdU antibody, 
BD Bioscience 347583) followed a paraformaldehyde/saponin-
based staining procedure as described in Rothaeusler and 
Baumgarth (31). Images taken from five replicates were visually 
scored for BrdU-stained cells.
cell Viability, Proliferation, and apoptosis
To investigate the effects of flavonoids on cell viability, primary 
murine CECs were cultured with and without tomato extracts at 
2% final concentration (v/v) for 3 days. In addition, CECs were 
cultured for 18 h to mimic the conditions in the wound healing 
assays. m-ICcl2 cells were trypsin treated to dissociate the cells and 
gently pipetted to maintain membrane integrity and minimize 
false-positive results. For CEC and m-ICcl2 assays, two antibody 
markers of early apoptosis were used, annexin V (BD Bioscience 
556570) and active Caspase 3 (BD Bioscience 550914) and a pro-
pidium iodide exclusion assay (BD Bioscience 556570) for non-
viable cells. Actively proliferating cells were stained with Ki-67 
(BD Bioscience 562899 and isotype control BV480), repeated 
three times. BrdU incorporation assays were performed as previ-
ously described. For both cell types, the assays were repeated three 
times. Stained cells were assayed by flow cytometry, according to 
the manufacturer’s protocols. The following gating strategy for 
flow cytometry analysis was used: single-cell events were gated 
for using forward and side scatter parameters. Following this, 
unstained cells and isotype controls were run. All flow cytometry 
and previously mentioned FACS data were analyzed using FloJo 
7 software (Tree Star, Inc.). Mean values and SD were calculated 
from three replicates.
statistical analyses
Excel was used as the statistical software for the data analyses. 
For comparing two groups, Student’s t-test were used. These 
assumed unequal variances to determine which of the mean 
values were significantly different with a hypothesized mean of 
0 and an alpha value set at 0.05 (the null hypothesis was rejected 
if the two-tailed p-value was <0.05). For comparing multiple 
groups, one-way ANOVA tests were used. using a 0.05 alpha 
setting. A null hypothesis was rejected if the F-value > F criti-
cal value. Statistically significant results (p < 0.05) are indicated 
with an asterisk symbol (*) in the figures. Non-significant results 
(p > 0.05) are indicated with a hash symbol (#).
ethical considerations
Animal experimentation was performed with University of East 
Anglia Animal Procedures Ethics Committee and UK Home 
Office approval (Protocol no. PPL 40/6325, 80/2355).
resUlTs
analysis of engineered Tomato  
Flavonoid content
The engineered tomatoes have been described before (23, 32) 
and the concentrations of the principal components in the wild-
type, high-anthocyanin, and high-flavonol extracts used in this 
study are given in Table 1. The high-anthocyanin extract showed 
a significant enrichment in the anthocyanin delphinidin and 
small increases in the flavonol rutin and the other components 
tested, including chlorogenic acid (Table  1). The high-flavonol 
extract showed substantial increases in glycosylated flavonols 
and chlorogenic acid levels (Table  1) as compared with the 
control (wild type) tomatoes. Aside from differences in concen-
trations of different flavonoids, the high flavonol extract had a 
higher overall flavonoid content (4943.26 µM) compared to the 
high-anthocyanin extracts (641.81 µM), see Table 1.
Flavonoids specifically inhibit gut  
Barrier Pro-inflammatory cytokine 
secretion
As the colonic epithelium receives the highest dose of dietary 
flavonoids, we investigated their effect on epithelial barrier 
FigUre 1 | Flavonoid-enriched tomato extracts inhibiting key pro-inflammatory cytokines and chemokines. An inflammatory response in primary murine colonic 
epithelial cells was initiated with microbe-associated molecular patterns, with and without tomato extracts. Cytometric bead arrays and flow cytometry was used  
to assay secreted cytokine and chemokine levels. Pro-inflammatory cytokines [(a), i,ii], anti-inflammatory cytokine IL-10 (B). A set of inflammatory bowel disease 
chemokines were inhibited [(c), i–v]. Y-error bars show SD values around the mean, n = 3. *Statistically significant (p < 0.05), #Not statistically significant (p > 0.05).
5
Tomlinson et al. Flavonoids Inhibit IBD by Kinase Signaling
Frontiers in Nutrition | www.frontiersin.org December 2017 | Volume 4 | Article 61
cytokine secretion using a primary murine CEC inflammation 
model. CECs were cocultured with several MAMPs: lipopoly-
saccharide, peptidoglycan, and muramyl dipeptide to initiate 
a broad inflammatory response in the presence or absence of 
tomato extracts. Using cytometric bead arrays, we assayed several 
key inflammatory cytokines from the same sample. The culture 
of CECs without MAMP stimulation produces a very low level 
of cytokine production (<10 pg/mL). Analysis showed that the 
addition of wild-type tomato extracts reduced IL-6 levels by 41% 
compared with the no extract controls (Figure 1Ai). However, the 
addition of the high-anthocyanin and the high-flavonol extracts 
had a pronounced inhibitory effect, with 84 and 90% IL-6 reduc-
tion, respectively (Figure 1Ai). TNFα secretion was also reduced 
to undetectable levels by addition of either high-anthocyanin 
or high-flavonol tomato extracts (Figure  1Aii). The levels of 
IL-10 with both high-anthocyanin and high-flavonol tomato 
extract addition remained comparable with values for control 
and wild-type tomato extract values (Figure  1B). Statistical 
analysis (ANOVA) showed that there were no significant effects 
of addition of different tomato extracts (p < 0.05) on IL-10 secre-
tion (Figure  1B). ANOVA analysis of the pro-inflammatory 
cytokines showed a significant difference (p < 0.05) compared 
with no extract and wild-type extract addition.
Flavonoids inhibit the epithelial secretion 
of a set of iBD chemokines
Addition of wild-type tomatoes had no effect on chemokine 
secretion (Figure 1Ci–v). The addition of the high-anthocyanin 
tomato extract inhibited the secretion of CXCL1 by 97%, and 
also completely inhibited CCL3, CCL4, and CCL5 secretion 
(Figure  1C). Complete inhibition of CXCL1, CCL3, CCL4, 
and CCL5 was also observed with the addition of the high-
flavonol tomato extract (Figure  1C). Both the high-flavonol 
and high-anthocyanin tomato extracts reduced CCL2 levels 
by 67 and 80% for anthocyanins and flavonols, respectively 
(Figure 1Cii).
FigUre 2 | Consequence of reduced chemokine levels on primary murine 
leukocyte and dendritic cell (DC) migration. FACS-sorted primary cells and 
Boyden chambers assays were used. Average number of transmigrated 
primary murine spleen CD45+ (leukocytes) and primary spleen CD11C+/
MHCII+ (DCs) are shown. The X-axis shows zero, no recombinant 
chemokines in the lower Boyden chamber (media-only control), and low 
levels replicated the mean value with 2% high-flavonol tomato extract 
addition. High represents colonic epithelial cells, induced with microbe-
associated molecular patterns, in the presence of wild-type tomato extract. 
Y-error bars show SD values around the mean, n = 3. *Statistically significant 
(p < 0.05). #Not statistically significant (p > 0.05).
TaBle 2 | Checker board analysis of Boyden chamber assays.
Upper chamber
lower  
chamber
0 High
0 1 (9.85%±) 0.61 (10.79%±)
High 2.56 (15.24%±) 1 (8.59%±)
Ratios of counted cells, both by hemocytometer and FACS. 0 values refer to serum 
free HBSS only chamber, High refers to the levels of chemokines seen with MAMP 
stimulated colonic epithelial cells and 2% wild-type aqueous extract. n = 3. Mean 
values are shown with SD.
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lower epithelial chemokines lead to 
reduced leukocyte and Dc chemotaxis
Transwell migration (Boyden chamber) assays revealed an 
increased number of leukocytes (61%) migrating toward 
a high-chemokine gradient. High chemokines (Figure  2) 
represent CECs, induced with MAMPs, in the presence of 
wild-type tomato extract. Importantly, a proportionally larger 
number of DCs had transmigrated (78%) than in the media-
only control (Figure 2). However, this migration was reduced 
with low-chemokine levels, representing engineered tomato 
extract addition (based on average chemokine levels with 2% 
high-flavonol tomato extract addition) (< 30% leukocytes and 
<  33% DCs as compared with the media-only control). The 
differences between the low- and high-chemokine groups were 
found to be significant (p < 0.05, t-test). Checker board analysis 
revealed a strong chemotactic and not a chemokinetic response 
(Table 2).
Flavonoids suppress several  
Pro-inflammatory epithelial  
signaling Pathways
To investigate potential flavonoid molecular targets, we assayed 
key inflammatory kinase signaling pathways known to play a role 
in IBD in both human and rodent studies (33–35). An ELISA 
assay with phospho-epitope specific capture antibodies was used, 
along with primary murine CEC lysates, to assay the activation 
state of NF-κB, SAPK/JNK, p38 MAPK, and STAT3 kinases.
Colonic epithelial cells treated with wild-type tomato extract 
showed a small, but significant decrease in SAPK/JNK activity 
(Figure  3). High-flavonol extracts dramatically reduced the 
activity of SAPK/JNK (Figure 3), and high-anthocyanin tomato 
extract reduced the activity of SAPK/JNK by 87% (Figure 3) as 
compared with no tomato extract controls. These differences 
were all found to be significant (p < 0.05, ANOVA analysis and 
t-test). The high-flavonol extract reduced p38 MAPK activa-
tion by 70% as compared with the no-tomato extract control 
(Figure  3). High-anthocyanin extracts reduced p38 MAPK 
activation by 75% (Figure 3). Wild-type extract inhibited p38 
MAPK activation by 43% (Figure  3). The wild-type extract 
had a significant effect on p38 MAPK activation as did high-
anthocyanin and high-flavonol extracts. The high flavonol 
significantly inhibited p38 MAPK phosphorylation more than 
the high anthocyanin extract. These differences were found to 
be significant (p < 0.05, ANOVA and t-test).
None of the tomato extracts showed a significant inhibition 
of the intestinal wound healing-associated STAT3 pathway 
(p < 0.05, ANOVA) (Figure 3). However, STAT3 activation was 
significantly induced with MAMP induction (Figure 3).
Flavonoids Do not effect intestinal  
Wound healing
As none of the high-flavonoid tomato extracts affected activation 
of the STAT3 pathway (Figure 3), we investigated the processes 
linked to STAT3 function further, by looking at apoptosis, cel-
lular proliferation, and migration. Scratch wound assays (m-ICcl2 
cells) were used to investigate cellular migration at a wound site. 
CECs are semi-adherent, as such scratch wound assays could 
not be performed. Addition of 2% wild-type tomato extract or 
either high-anthocyanin or flavonol tomato extract addition had 
no effects on m-ICcl2 cell migration (Figures 4Ai,ii–Di,ii; Figure 
S1 in Supplementary Material). BrdU incorporation assays on 
the m-ICcl2 monolayer showed that addition of either flavonoid-
enriched extract had no effect on cellular proliferation at 2% 
(Figures  4Aiii–Diii). Figure  4E shows that at 2% the tomato 
extracts had no effect on either CEC apoptosis or cell viability 
(p <  0.05, ANOVA). Figure  4F shows that they also had no 
adverse effect on CEC proliferation (p < 0.05, ANOVA). Tomato 
extracts enriched with flavonoids at 2% had no significant effect 
on apoptosis or cell viability after 3 days of m-ICcl2 culture (Figure 
S2 in Supplementary Material) (p < 0.05, ANOVA). In conclu-
sion, flavonoids had no observed effects on the wound healing 
processes associated with IBD remission.
FigUre 3 | Phospho-specific ELISA assay used with primary murine colonic epithelial cells, induced inflammatory response via microbe associated molecular 
pattern (MAMP) addition. Tomato extracts were added prior to MAMP addition. Y-error bars show SD values around the mean, n = 3. *Statistically significant 
(p < 0.05). #Not statistically significant (p > 0.05).
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DiscUssiOn
We have taken a unique approach to assay the anti-inflammatory 
actions of flavonoids, using tomatoes engineered to express high 
levels of flavonoids (either anthocyanins or flavonols) to allow 
comparative analysis with an isogenic whole food matrix (32). 
Previous studies have focused on single polyphenol standards 
or whole foods with no-comparable control (36). The aqueous 
tomato extracts do not include the hydrophobic carotenoid lyco-
pene, allowing the flavonoid effects to be assayed independently of 
this known biologically active compound, normally in tomatoes.
Our study used transient cultures of primary mouse CECs 
that have been demonstrated to release a wide range of cytokines 
and chemokines in response to bacterial antigen stimulation 
(26), in an analogous way to human CECs (37). They also receive 
the highest topological doses of dietary flavonoids in the body 
(14). Flavonoids are known to be readily absorbed from the gut 
lumen and taken up at the apical surface of the epithelial mon-
olayer via active transport (38). Interestingly, a previous study 
has concluded that there was no further translocation across the 
basolateral side, to the lamina propria (39), indicating flavonoid 
accumulation in epithelial cells.
For the results presented in our study to have a clinical 
impact, the flavonoids must be at achievable levels. Estimates 
of flavonoid levels consumed in the human diet range from 20 
to 1,000 mg/day (40) with the mean intake in Europe estimated 
to be 428  mg/day (41). Ingestion of 500  mg of polyphenols 
has been estimated to give local intestinal concentrations of 
about 300 µM (42). Rutin administered to rats at 10  mg/kg 
accumulated to a local concentration in the large intestine at 
220 µM (43). We believe that the levels of flavonoids used in this 
study are achievable by dietary means, although more extensive 
pharmokinetic analysis of different dietary flavonoids would be 
needed to support this interpretation.
The MAMPs in our CEC inflammation model have been 
previously shown to initiate CEC secretion of IL-6 and CCL2 
(26). The effect of flavonoids on chemokine secretion has been 
demonstrated for individual chemokines, such as IL-8 (the 
human equivalent to mouse CXCL1) and CCL2 (44), TNFα and 
IL-6 (15). Of particular interest is the ability of both the high-
flavonol and the high-anthocyanin tomato extracts to inhibit 
TNFα. Anti-TNFα immunotherapy is an effective treatment for 
IBD (45). TNFα has been shown in macrophages to be inhibited 
by flavonoids (46). Quercetin has been shown to decrease CCL3 
release from adipocytes and macrophages (47) and flavonoid 
inhibition of CCL4 and CCL5 secretion was observed in a study 
with macrophages infected with Chlamydia trachomatis (48).
The value of using engineered tomatoes as a complex com-
parative food model is demonstrated by the inhibition of IL-6 by 
the control wild-type tomato extract (Figure  1Ai). This would 
have been missed using polyphenol standards or whole foods 
without a comparative control. Missing the effects of the food 
matrix could lead to a possible overestimation of cytokine inhibi-
tion. The high-flavonol tomato extracts contained significantly 
higher amounts (over sevenfold) of total flavonoids compared 
with the high-anthocyanin extracts. This may explain the greater 
efficacy of the high-flavonol extracts at reducing markers of CEC 
inflammation. However, anthocyanins may actually have a higher 
efficacy, because similar effects were seen with significantly lower 
concentrations.
FigUre 4 | Effect of flavonoid-enriched tomato extracts on intestinal wound healing. [(a–D), i] cellular migration m-ICcl2-based cell assays at time Ohr scratch 
wounds. [(a–D), ii] The same scratched areas at 18 h post wounding. [(a–D), iii] The same scratched areas as [(a–D), ii], but with BrdU staining (proliferating cells). 
Representative images are shown. Colonic epithelial cell based assays for apoptosis and proliferation. (e) Apoptotic and non-viable CECs after 3 days of flavonoid-
enriched tomato extract addition at 2%, n = 3. (F) Proliferating (Ki-67+) CECs after 3 days coculturing with tomato extracts at 2%, n = 3. Y-error bars show SD 
values around the mean, n = 3. #Not statistically significant (p < 0.05).
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Analysis of the CEC produced Th2 immunoregulatory 
chemokine IL-10, revealed no effect with flavonoid exposure 
(Figure  1B), consistent with other studies (15), and suggests 
specific effects of flavonoids in repressing pro-inflammatory 
cytokines. This is of importance since IL-10 plays a key role in 
IBD, by inhibiting pro-inflammatory responses (49).
Assaying the activation state of several key pro-inflammatory 
signaling pathways revealed a significant inhibition of p38 MAPK 
phosphorylation by all the tomato extracts, including extracts 
of the wild-type comparator (Figure 3). However, significantly 
stronger effects were observed with both the high-anthocyanin 
and high-flavonol tomato extracts (Figure  3). p38 MAPK is 
believed to play a central role in the regulation of a wide range 
of immunological responses, including pro-inflammatory 
responses (50) and in IBD (51). In intestinal epithelial cell lines, 
p38 activation regulates IL-8 expression (the mouse homolog 
of which is CXCL1) (52). CXCL1, CCL2, and CCL5 secretion is 
also linked to p38 MAPK activation in intestinal epithelial cells 
(53, 54). The SAPK/JNK kinase pathway also plays a key role in 
regulating pro-inflammatory responses in IBD (55). SAPK/JNK 
9Tomlinson et al. Flavonoids Inhibit IBD by Kinase Signaling
Frontiers in Nutrition | www.frontiersin.org December 2017 | Volume 4 | Article 61
is known to regulate CCL5 expression in intestinal epithelial 
cells (56) and IL-6 expression in the colon (57). Of the major 
intracellular signaling cascades examined (NF-κB, p38 MAPK, 
ERK, and SAPK/JNK), we found inhibition of the activation 
state of two; p38 MAPK and SAPK/JNK. The ERK pathway was 
not investigated because its primary role in inflammation is in 
T-cell activation (58).
Considering that anthocyanins and flavonols cause compa-
rable biological effects, it is likely that they target similar steps 
in key pro-inflammatory signaling pathways. It remains unclear 
whether flavonoids exert their biological effects by interactions 
with cell surface proteins or cytoplasmic/nuclear proteins, and 
this is an area requiring further investigation. As flavonoids are 
thought to be pleiotropic, their effects are could involve a combi-
nation of molecular targets.
A commonly cited flavonoid molecular target is the NF-κB 
kinase pathway (17). We did not observe significant levels of 
the NF-κB p65 subunit or its inhibitor IκBα, or phosphorylated 
levels of NF-κB p65 in our CEC ELISA-based assays. This is con-
sistent with evidence from studies using NF-κBEGFP transgenic 
mice which shows NF-κB expression in the colon to be confined 
to lamina propria mononuclear cells (59). NF-κB in CECs has 
been reported to be involved in intestinal homeostasis, including 
maintaining epithelial integrity, and not in any pro-inflammatory 
response (60). TLR signaling (as in an MAMP-induced inflam-
matory response) in CECs also does not involve NF-κB activa-
tion (61).
We did not observe an inhibition of the STAT3 kinase pathway. 
STAT3 activation is involved in intestinal barrier maintenance, 
via regulation of epithelial cell proliferation and survival (62). 
This provides a molecular explanation as to why no effect on 
apoptosis, proliferation, or migration was seen with flavonoid 
addition (see Figure 4). STAT3 is also important for the efficient 
regeneration of the epithelium in response to injury (63). In mice, 
STAT3 activity co-localizes to proliferating intestinal crypt cells 
near the wound site (21).
Our study highlights the inhibitory effects of flavonoids on 
cytokine and chemokine release and the inhibition of the major 
inflammatory kinase pathways induced in inflammation and the 
consequences for DC migration. Under homeostatic conditions, 
a steady-state population of DCs patrols the epithelium, acting as 
sentinel cells, to promote tolerance (64). However, recruitment of 
large numbers of activated DCs in IBD from the lamina propria 
to the epithelium is a chemokine-driven process (64). First, 
enterocytes (the main epithelial cell) along with sentinel DCs 
sense bacterial-derived antigens (MAMPs) via pattern recogni-
tion receptors such as toll-like receptors (TLRs) and NOD2, then 
secrete chemokines to rapidly recruit more DCs (64). Epithelial 
cells also recruit unconditioned monocytes that develop into 
inflammatory DCs for the induction of immunity (65). DCs have 
a vital role in IBD, demonstrated when DCs are ablated during 
DSS-induced colitis and disease manifestation is ameliorated 
(9). Further evidence comes from colitis being associated with 
an increase in DCs in the colonic mesenteric lymph nodes and 
blocking interactions between DCs and T cells prevents colitis (9).
A proposed model of DC migration following exposure to 
high-flavonoid levels is shown in Figure S3 in Supplementary 
Material. To the best of our knowledge, this is the first time that 
the inhibition of a set of key IBD chemokines has been demon-
strated by flavonoids from the epithelial barrier (using primary 
cells, instead of immortalized cell lines). Our results highlight 
a mechanism by which flavonoids could exert their effects in 
making the epithelial barrier hyporesponsive, by reducing the 
responsiveness of key pro-inflammatory kinase signaling path-
ways to the microbiota in a genetically susceptible individual. 
This should help direct future in  vivo and human intervention 
studies. We show the benefits of using engineered tomatoes as 
a research tool in contrast to purified standards, or whole foods 
rich in a diverse number of biologically active compounds that 
have no comparator control.
The role of diet in modulating the state of the immune system 
is an area with huge potential to improve the quality of life of 
those living with chronic conditions and to reduce some of the 
burden imposed on our health system.
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FigUre s1 | Effect of flavonoids on the extent of wound closure on an m-ICcl2 
cell line-based scratch wound model, percentage closure calculated by wound 
diameter at T-0 compared with the same wound area at T-18 h using scaled 
wound width measurements. Y-error bars show SD values around the mean, 
n = 3. #Not statistically significant (p > 0.05).
FigUre s2 | Effect of flavonoid-enriched tomato extract addition on m-ICcl2 
cell-line viability. (a) Apoptosis and cell viability were assayed with antibodies to 
annexin V and the active form of Caspase 3, along with a propidium iodide 
exclusion assay. (B) Proliferation, with an BrdU incorporation assay and Ki-67 
antibody staining. Y-error bars show SD values around the mean, n = 3. #Not 
statistically significant (p > 0.05).
FigUre s3 | Proposed model for flavonoid inhibition of gut barrier recruitment  
of dendritic cell (DCs) during inflammation. ▲ represents microbe-associated 
molecular pattern (MAMP). (a) The normal situation of inflammation in response 
to MAMP detection on the apical side of epithelial cells. DCs are shown migrating 
toward a chemokine gradient. (B) The situation with dietary flavonoid intervention.
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